Cohen Joshua B 4

4 · Amylyx Pharmaceuticals, Inc. · Filed Jan 20, 2026

Form 4

Period: 2026-01-15

DirectorCo-Chief Executive Officer

Transactions

Exercise/Conversion
Common Stock
2026-01-15$7.57/sh+197,182$1,492,668→ 3,514,814 total
Sale
Common Stock
[F1][F2]
2026-01-15$13.59/sh−136,193$1,850,795→ 3,378,621 total
Exercise/Conversion
Common Stock
2026-01-16$7.57/sh+2,818$21,332→ 3,381,439 total
Sale
Common Stock
[F1][F3]
2026-01-16$13.83/sh−1,974$27,299→ 3,379,465 total
Exercise/Conversion
Stock Option (Right to Buy)
[F4]
2026-01-15−197,182→ 2,818 total
Exercise: $7.57Exp: 2026-02-19→ Common Stock (197,182 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
[F4]
2026-01-16−2,818→ 0 total
Exercise: $7.57Exp: 2026-02-19→ Common Stock (2,818 underlying)

Footnotes (4)

[F1]Reflects shares sold to cover option cost and tax obligations upon the option exercise pursuant to a preset sales plan adopted by the reporting person on November 12, 2025.
[F2]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.26 to $13.76. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
[F3]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.82 to $13.835. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
[F4]This option is fully vested and exercisable. The option is due to expire on February 19, 2026.

Signature

/s/ Joshua B. Cohen|2026-01-20

Documents

1 file